Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple Turns 50: From Garage Startup to AI Crossroads 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
(4) - EconoTimes)
CAMBRIDGE, Mass., Aug. 31, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on August 31, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twelve individuals hired by Sarepta in August 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 63,715 shares of Sarepta's common stock. The options have an exercise price of $40.29 per share, which is equal to the closing price of Sarepta's common stock on August 31, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
